Vertex Pharmaceuticals (VRTX) Short-term Investments (2009 - 2026)

Vertex Pharmaceuticals has reported Short-term Investments for 18 years, with the latest figure at $1.8 billion in Q1 2026.

• For the quarter ending Q1 2026, Short-term Investments rose 14.89% year-over-year to $1.8 billion; the trailing twelve-month figure through Mar 2026 stood at $1.8 billion (up 14.89% YoY), and the FY2025 full-year result was $1.5 billion, down 1.49% from the prior year.
• Short-term Investments for Q1 2026 stood at $1.8 billion, up from $1.5 billion in the prior quarter.
• The five-year high for Short-term Investments was $1.8 billion in Q1 2026, with the low at $274.5 million in Q4 2022.
• Average Short-term Investments over 5 years is $1.1 billion, with a median of $1.1 billion recorded in 2023.
• Year-over-year, Short-term Investments plunged 62.39% in 2022 and surged 209.36% in 2023.
• Tracing VRTX's Short-term Investments over 5 years: stood at $274.5 million in 2022, then surged by 209.36% to $849.2 million in 2023, then soared by 82.09% to $1.5 billion in 2024, then slipped by 1.49% to $1.5 billion in 2025, then climbed by 15.13% to $1.8 billion in 2026.
• The last three Short-term Investments figures came in at $1.8 billion (Q1 2026), $1.5 billion (Q4 2025), and $1.3 billion (Q3 2025), per Business Quant data.

Peer Comparison